The review, conducted by Charlotte S. Rye, Gemma Baker, and Amy L. Milton, brings together preclinical and clinical studies examining how these drugs interact with the neurocircuitry of stress. The timing is significant. Stress-related disorders represent one of the largest burdens of psychiatric disease worldwide, yet current pharmacological options—primarily selective serotonin reuptake inhibitors and benzodiazepines—leave many patients without adequate relief, and they often take weeks to exert their effects, if they work at all. Against that backdrop, the possibility that a widely prescribed, well-characterized class of metabolic drugs could be repurposed for psychiatry has generated intense interest among clinicians and neuroscientists alike.

To understand why the idea is plausible at all, one has to appreciate just how pervasive GLP-1 signaling is in the central nervous system. GLP-1 is produced in the brainstem by neurons of the nucleus tractus solitarius, which project widely to structures including the hypothalamus, amygdala, hippocampus, and prefrontal cortex—a network that overlaps substantially with the circuits implicated in the stress response and in fear learning. GLP-1 receptors are G-protein-coupled receptors that, when activated, enhance cAMP signaling, reduce neuronal excitability in certain populations, and modulate neurotransmitter release. Crucially, animal studies have shown that activation of these receptors can dampen hypothalamic-pituitary-adrenal axis activity, the endocrine engine of the stress response, reducing corticosterone release in rodents exposed to stressors.

The systematic review synthesized findings from rodent models of stress and trauma as well as the limited clinical data available in humans. In preclinical work, GLP-1 receptor agonists such as exendin-4 and liraglutide have been reported to attenuate anxiety-like behavior in paradigms like the elevated plus maze and open-field test, and to modulate fear conditioning and extinction—processes directly relevant to PTSD. Some studies suggest that these effects may be dissociated from the drugs’ metabolic actions, appearing at doses or in experimental conditions where effects on food intake and body weight are minimal or absent. That dissociation matters enormously for the drug-repurposing argument, because it implies the central nervous system effects may be pharmacologically separable from the peripheral metabolic profile that defines these drugs clinically.

The mechanisms proposed in the reviewed literature converge on several themes. Chronic stress is increasingly understood as a state of neuroinflammation, oxidative stress, and impaired synaptic plasticity in the hippocampus and prefrontal cortex. GLP-1 receptor agonists have demonstrated anti-inflammatory properties in the brain, reducing microglial activation and pro-inflammatory cytokine signaling in animal models. They also appear to promote neuroplasticity, enhancing markers such as brain-derived neurotrophic factor and supporting neurogenesis in the dentate gyrus. In parallel, by normalizing HPA axis tone, they may counteract the chronic glucocorticoid exposure that erodes dendritic complexity in prefrontal neurons and drives amygdala hyperreactivity—hallmarks of the chronically stressed brain.

Clinical evidence, however, remains far thinner than the preclinical promise. The review identifies observational and early-phase studies hinting at mood improvements in patients taking GLP-1 receptor agonists for diabetes or obesity, and some reports of reduced depressive symptoms. But the authors are careful to underscore the caveats. Improvements in mood among patients losing significant weight could reflect the psychological benefits of metabolic change rather than a direct psychotropic effect. Confounding by indication is pervasive: people prescribed these drugs differ systematically from those who are not. And randomized controlled trials specifically powered to detect effects on stress-related disorders are, at present, scarce or absent. The review thus positions itself not as a declaration of efficacy but as a rigorous map of what is known and, more importantly, what is not.

The translational challenges the authors highlight are considerable. Dosing is one: the exposures used in rodent studies rarely map cleanly onto the human doses that produce weight loss, and achieving central effects without metabolic side effects may require careful titration or the development of brain-targeted analogs. Timing is another. Stress-related disorders involve learned fear and its pathological persistence, and the ideal intervention might need to be timed to specific windows of fear extinction or memory reconsolidation, raising questions about whether chronic dosing—the format in which GLP-1 agonists are currently delivered—is optimal for psychiatric indications. Sex differences, too, demand attention, given that stress-related disorders such as PTSD and depression show pronounced female predominance, while much of the preclinical literature has historically relied on male rodents.

Safety considerations also loom large in psychiatric populations. GLP-1 receptor agonists carry known risks including nausea, vomiting, and, more rarely, pancreatitis and gallbladder disease. More troubling for psychiatric repurposing is the recent scrutiny of neuropsychiatric adverse events: regulators have examined reports of suicidal ideation in some users, although large observational analyses have generally not confirmed an elevated risk and some suggest possible protective associations. Patients with severe stress-related disorders are themselves at elevated suicide risk, making careful pharmacovigilance and dedicated psychiatric safety monitoring essential in any future trials. The review emphasizes that enthusiasm must be tempered by these unresolved questions.

Still, the strategic case for pursuing this line of research is compelling. GLP-1 receptor agonists have an established safety record in millions of patients, well-characterized pharmacokinetics, and long-acting formulations that could support once-weekly dosing—advantages that make repurposing dramatically faster and cheaper than de novo drug development. If the neuroprotective, anti-inflammatory, and HPA-modulating effects seen in animal models can be translated, the payoff could extend beyond stress-related disorders to comorbid conditions common in metabolic disease, where depression, anxiety, and obesity frequently co-occur. The bidirectional relationship between metabolic dysfunction and psychiatric illness—each worsening the other—suggests that a drug acting on both axes could break a vicious cycle.

The review’s authors call for a structured research agenda: rigorously designed randomized controlled trials in well-defined stress-related disorder populations, studies that dissociate central from metabolic mechanisms, investigation of dosing and treatment timing, and attention to sex as a biological variable. They also urge basic scientists to pin down the receptor-expressing neuronal populations responsible for the anxiolytic and fear-extinction effects, work that could guide the design of next-generation agonists with tailored central profiles. Whether GLP-1 receptor agonists ultimately earn a place in psychiatry’s formulary remains an open question, but this systematic review makes a persuasive case that the question deserves to be asked at scale. The molecule that reshaped metabolic medicine may yet have something to say about the mind—and the scientific community is now listening.